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Objectives: To establish an inducible system for
controlled ZBTB16 protein expression in a renal adeno-
carcinoma cell line.
Methods: The Tet-On 3G Inducible Expression System
from Clontech was used to generate a tetracycline-
regulated ZBTB16 expression system in the ACHN
renal adenocarcinoma cell line.
Results: The Tet-On 3G system successfully controlled
the basal level of ZBTB16 with no detectable protein
expression when doxycycline was absent from the culture
medium. The addition of doxycycline induced ZBTB16
protein expression with as low as 20 ng/ml of
doxycycline.
Conclusion: The firm regulation of transcription factor
expression in cancer cell models is very important in
investigating their biological roles. Many transcription
factors, such as ZBTB16, will carry on their biological
activities even with minimal expression levels. The Tet-
On 3G system was essential in controlling the basal
expression to prevent transcription leakage and
providing a tightly regulated method for expressing
ZBTB16 in a manner resembling physiological
conditions.
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B.A. Suliman360IntroductionGlobally, cancer is one of the leading causes of death, and
finding a suitable treatment option for cancer cells is a major
challenge for researchers in the medical field. Many cancer-
based therapeutics are cytotoxic and induce death in
actively proliferating cells. This, however, is beneficial only in
high-grade tumours. In many cancers, such as early stage
prostate cancer1 or primary lesions of renal carcinoma,2
malignant cells proliferate almost like normal cells, making
them a difficult target for chemotherapy. Developing
therapies by targeting certain molecules that are crucial for
the proliferation, metastasis and survival of cancer cells is a
major focus in cancer research. Several approaches have
emerged in the field, including targeting cell surface
antigens,3 proteins that are over-expressed in specific ma-
lignant cells4 and transcription factors that positively drive
the cell cycle.5
The promyelocytic leukaemia zinc finger (ZBTB16, PLZF
or ZNF145) protein is a transcriptional repressor belonging
to the Kru¨ppel-like zinc finger family of proteins.6 It plays a
key role in various developmental and biological processes
and has been implicated in leukaemogenesis and
oncogenesis.7e11 ZBTB16 expression is required to
maintain the proliferative as well as the self-renewal capac-
ity of many stem and early progenitor cells. This requirement
is maintained even after maturation to regulate the differ-
entiation of these cells.8 A genome-scale high-density oligo-
nucleotide array showed that ZBTB16 was expressed in
many tissue types. The study also showed that ZBTB16
expression was present under normal physiological condi-
tions in various tissue types, but the level of expression was
significantly decreased in many cancer cell types.12 It was
also shown that ZBTB16 expression is required to sustain
the pluripotency of stem cells, but when those cells
differentiate toward more functional and mature cells, the
expression of ZBTB16 decreases, allowing certain
signalling pathways to be activated.13
ACHN is human renal carcinoma cell line that was
developed from a pleural effusion of a 22-year-old Caucasian
male diagnosed with renal cell carcinoma. It grows as an
adherent cellular group with a doubling time of approxi-
mately 16 h and shows no detectable ZBTB16 expression.14
This cell line has been widely used as a cell model for
invasive renal adenocarcinoma.15e18
The study of transcription factor activity in cancer cells is
usually accompanied by the overexpression of that tran-
scription factor using molecular cloning to study its effect on
different biological systems. The overexpression process is
mainly carried out by cloning the open reading frame (ORF)
of the protein of interest to an expression plasmid that is
transfected into cancer cells. This might overwhelm the cells
with large amounts of that specific protein because the
plasmid is constitutively expressed by the cell’s transcrip-
tional machinery. Therefore, a better system of controlled
protein expression is required for use in different biological
experiments or assays.
The Tet-On system is a molecular technique for inducible
gene expression which utilizes specific operator motifs in the
promoter sequence that bind certain proteins in order for
transcription to be activated.19 Another molecular techniquefor controlling protein expression is the addition of a
destabilizing domain (DD) that can be fused to either end
of the protein of interest. The DD would cause the direct
targeting of DD-fused protein by proteasomal degradation
complexes in the cell unless the DD is neutralized with a
small molecule called Shield1 (Clontech, USA). Shield1
works by masking the DD binding domain and making it
inaccessible to the degradation complex.20 In this study, I
have utilized both approaches to generate a stable renal
adenocarcinoma cell line in which the expression of
ZBTB16 can be tightly regulated.
Materials and Methods
We began by constructing the ZBTB16 expression
plasmid that would be under control of the tet-induced
promoter from Clontech (Figure 1). First, the ZBTB16
ORF from pLv129 (GeneCopoeia, USA) was cut with
EcoRI and NotI-HF (NEB, USA) and purified using gel
electrophoresis. pcDNA3.1-B (Life Technologies, USA) was
also linearized using the same restriction enzymes and puri-
fied using gel electrophoresis. ZBTB16 ORF was then ligated
to the linearized pcDNA3.1-B to fuse ZBTB16 with the V5
epitope and was subsequently transformed into DH5a cells
(Invitrogen, USA) that were cultured in Carbenicillin-
containing plates. The plasmid DNA was extracted from
the DH5a E. coli using column chromatography (Promega,
USA) and colony PCR was performed to verify the ZBTB16
ORF orientation.
Next, ZBTB16-V5 was amplified using Phusion PCR
(NEB, USA) with primers that would add both BglII and
EcoRI restriction sites to the 50 and 30 ends, respectively. The
PCR product was purified and directly ligated to pJet1.2
(ThermoScientific,USA) and then transformed inDH5a that
were grown in Carbenicillin-containing plates. The plasmid
DNA was extracted from the DH5a E. coli and digested with
BglII and EcoRI to release ZBTB16-V5 with sticky ends.
pTagRFP-N (Evrogen, Russia) was linearized with the same
enzymes and ZBTB16-V5 was fused to the N-terminal end of
TagRFP. The ligation product was transformed in DH5a,
which was grown in kanamycin-containing plates.
Once again, TagRFP-ZBTB16-V5 was amplified using
Phusion PCR with primers that would add both BamHI and
EcoRV restriction sites to the 50 and 30 ends, respectively.
The PCR product was purified and directly ligated to pJet1.2
and then transformed in DH5a, which was grown in
Carbenicillin-containing plates. The plasmid DNA was
extracted from the DH5a E. coli and digested with BamHI
and EcoRv to release TagREFP-ZBTB16-V5 with sticky
ends. pTRE-Cycle3 (Clontech, USA) was linearized with the
same enzymes and TagRFP-ZBTB16-V5 was ligated into the
BamHI and EcoRV sites. The ligation product was trans-
formed in DH5a, which was grown in Carbenicillin-
containing plates.
Generating the ZBTB16 inducible-expression system
required two steps of transfections and selections: the first to
introduce the tetracycline 3G trans-activator needed for Dox
binding and the second to introduce the ZBTB16 expression
construct. To generate stable ACHN cells expressing the
trans-activator protein, 1 mg of pCMV-3G plasmid was
transfected in 5  104 ACHN cells using the X-fect reagent
Figure 1: ZBTB16 inducible fusion protein construct. ZBTB16 ORF fused to TagRFP and V5 and cloned into the tet-inducible pTight
plasmid. This plasmid has a bi-directional promoter in which ZsGreen is also induced upon Dox treatment.
The generation of a ZBTB16-inducible expression system 361(Clontech, USA) at 80% confluency for 48 h. Twelve
different clones were isolated after G418 selection (800 mg/
ml) of the transfected cells over two weeks. The amount of
expression of the trans-activator protein was assessed by
transfecting the 12 clones with the tet-inducible luciferase
construct pTRE-Luc and comparing the basal expression
levels of luciferase before Dox treatment to that after Dox
treatment for 24 h. Accordingly, the cells were either un-
treated or treated with 500 ng/ml Dox and then lysed and
processed for luciferase activity. Clone #5 designated
ACHN:3G, which was selected as the best candidate from
the other 11 clones, was further transfected as previously
discussed with 1 mg of pTRE-Cycle3-pTagRFP-ZBTB16-V5
and selected by puromycin (3 mg/ml) for 10 days before
isolating monoclonal colonies.Results
To test the expression pattern of ZBTB16 after creating
the TagRFP-ZBTB16-V5 expression plasmid, it was co-
transfected with the trans-activator plasmid into HeLa cells
for microscopic examination and for western blot analysis.
The expression of ZBTB16 protein was comparable to that
of the original plasmid pLv129 by using both Anti-ZBTB16
and anti-V5 antibodies (Figure 2). ZBTB16 expression also
showed typical nuclear-focused expression in HeLa cells af-
ter 500 ng/ml Dox induction for 24 h (Figure 3). Moreover,
lower doses of Dox were also able to induce a detectable
protein expression of ZBTB16 protein, while no protein
expression was seen in the absence of Dox (Figure 4).Figure 2: Protein expression of different ZBTB16 constructs.
Western blot analysis showing ZBTB16 expression in HEK293
cells after transfection with the designated plasmid to test the tet-
inducible promoter. pTagRFP-ZBTB16-V5 expression was
detected using V5 antibodies as well as ZBTB16-specific
antibodies.Furthermore, ZBTB16 was strongly expressed in the
absence of Shield1, which indicates that the destabilizing
domain does not promote the proteasomal degradation of
the ZBTB16 protein.
To test the clones expressing the 3G trans-activator that
are to be chosen for stable cell selection, luciferase levels were
compared between the induced state after Dox treatment and
the baseline levels without Dox treatment (Figure 5) and the
clone with the highest induction rate was chosen. ACHN
clone #5 showed minimal basal luciferase activity and a
high induction rate when compared to other ACHN
clones, the cells also showed no significant morphological
changes to the parental ACHN cells.
ACHN clone #5 was further transfected with the
ZBTB16-expression plasmid pTRE-Cycle3-TagRFP-
ZBTB16-V5-His. Twelve different clones were isolated after
double selection with puromycin and G418 of the transfected
cells over 10 days. Western blot analysis showed that clone
#5-7 expressed the highest amount of ZBTB16 protein after
1 mg/ml Dox induction for 24 h (Figure 6). Furthermore, theFigure 3: Fluorescence microscopy examination of the ZBTB16
inducible system in HeLa cells. pTagRFP-ZBTB16-V5 plasmid
was transfected in HeLa cells and the cells were treated with
500 ng/ml of Dox for 24 h and imaged under confocal microscopy.
The cells exhibited nuclear-focused ZBTB16 expression seen in red
for the expression of TagRFP (top) as well as green fluorescence
for the expression of ZsGreen (bottom).
Figure 4: ZBTB16 inducible expression system in HeLa cells.
pTagRFP-ZBTB16-V5 plasmid was transfected into HeLa cells
and treated with increasing doses of Dox (10, 20 and 50 ng/ml) for
24 h. The cells were lysed and ZBTB16 expression was detected by
western blot using V5 antibodies.
Figure 6: ACHN clones expressing different amounts of ZBTB16
after Dox treatment. ACHN clones (originating from Clone #5)
were treated with 1 mg/ml Dox and lysed for western blot analysis.
ACHN clone #5-7 showed maximal expression of PZLF after 24 h
of treatment and was subsequently used as the cell model and
designated ACHN:ZBTB16.
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assessed by treating the 12 clones with 500 ng/ml Dox and
comparing the fluorescence intensity of the cells before
Dox treatment to that after Dox treatment for 12 h. Ten
out of twelve clones showed no detectable fluorescence
without Dox treatment and two clones showed minimal
amounts of fluorescence and were excluded from the
experiment. ACHN clones #5-7 showed the highest level of
inducibility in terms of green fluorescence (Figure 7) after
Dox treatment with detectable fluorescence in Dox
absence. This double selected ACHN clone was designated
ACHN:ZBTB16. ACHN clone #5, which was only selected
by G418 and expresses the trans-activator, was used as a
control and was designated ACHN:control, as it did not
harbour the ZBTB16-expression plasmid and would not
manifest any Dox-mediated ZBTB16 effects. This would also
be helpful in determining the biological effects of Dox onFigure 5: Inducibility of ZBTB16 in different clones of
ACHN:3G. Twelve single-cell-derived clones from ACHN cells
were isolated and tested for the expression of the 3G trans-
activator by transfecting the pTRE-Luc construct and quanti-
fying luciferase activity. Basal as well as Dox-induced luciferase
was assessed and used to select the best clone for antibiotic se-
lection to generate a stably selected cell line.ACHN cells when comparing ACHN:control to parental
ACHN cells.
The ability of Shield1 to control the expression levels of
ZBTB16 in the double-selected ACHN:ZBTB16 cells was
tested again by treating the cells with 500 ng/ml Dox in the
absence or presence of 0.5 mM Shield1 protein for 24 h.
Again, there was no noticeable effect of Shield1 on the
amount of ZBTB16 protein in our cell model (Figure 8).
Discussion
Transcription factors play a very important role in many
intertwined biological functions. Understanding the extent
of their involvement in certain molecular signalling pathways
is key to discovering novel ways to tackle their targets.
Additionally, the firm regulation of their expression in cancer
cell models is very important in investigating their biological
involvement in carcinogenesis. Many transcription factors
including ZBTB16 will carry on their biological activities,
such as driving the cell cycle or promoting cellular growth,
even with minimal expression levels. Many transcription
factors, including ZBTB16, are under heavy spatial and
temporal regulatory mechanisms. The overexpression of
transcription factors by regular transfection methods may
result in high protein expression levels that do not represent
the physiological condition of actively growing cells. This
would prevent researchers from studying the effect of that
transcription factor on certain signalling pathways without
sacrificing reliability.
In this study, I used the Clontech Tet-inducible system to
regulate the expression of ZBTB16 in order to study the
biological roles of this transcription factor on different as-
pects of cancer cell biology. ZBTB16 is required for stem cell
self-renewal and survival, and its expression regulates the cell
cycle through many key mediators including Cyclin-D1 and
Myc.21 However, for some cancer cells to escape the effect of
ZBTB16, its expression is down-regulated throughout
carcinogenesis and those signalling pathways are relieved
from its repression.13 This required a biological system in
which the expression of ZBTB16 protein can be
manipulated and adjusted but with tight regulation that
would produce a complete transcriptional silencing when
required.
Figure 7: ACHN:ZBTB16 showing ZsGreen expression under fluorescence microscopy. Stably selected ACHN:ZBTB16 cells were either
un-treated (left) or treated with 500 ng/ml Dox (right) for 12 h and then imaged under confocal microscopy. ACHN:ZBTB16 showed a
similar morphological phenotype to the parental cells.
The generation of a ZBTB16-inducible expression system 363The Tet-On 3G system from Clontech was used to utilize
the 3rd generation tet-promoter that was shown to provide a
very low background activity in the absence of Dox.22 The
bi-directional pTRE plasmid was used to clone ZBTB16
ORF and produce the ZBTB16 expression plasmid
(Figure 1). The pTRE plasmid also contained another layer
of control offered by Clontech, namely the ProteoTuner
Shield System.23 The system works on the protein level by
adding a DNA sequence, called the destabilization domain,
to the sequence of the protein-of-interest that makes it tar-
geted by proteasomal degradation machineries inside the
cell.24 The addition of a small molecule called Shield1 would
protect the protein from proteasomal degradation and allow
the levels of the protein to rapidly increase with theFigure 8: No effect of Shield1 on ACHN:ZBTB16 cells after Dox
treatment. Stably selected ACHN:ZBTB16 cells were treated with
500 ng/ml of Dox either in the presence or absence of 0.5 mM
Shield for 24 h and then analysed for ZBTB16 expression using V5
antibodies. Shield showed no effect on PZLF expression levels and
was considered ineffective in this system.continued addition of Dox to the culture medium.
Unfortunately, the second layer of control using the
ProteoTuner Shield System was not effective in our
study. The absence of Shield1 in the culture medium did
not decrease the protein levels as it should have, and
ZBTB16 was effectively expressed by ACHN:ZBTB16 cells
with the addition of Dox alone (Figure 8). Similar results
were obtained even prior to the stable selection because
HeLa cells that were transiently transfected with the
ZBTB16 expression plasmid did not respond to the absence
of Shield1 and because ZBTB16 was also expressed by the
addition of Dox alone (Figure 4). This shows that the
Shield system was not effective after adding the ZBTB16
ORF to the original plasmid. Due to time constraints, the
destabilization domain was not transferred to C-terminus
of ZBTB16 ORF to check whether it would successfully
control the protein expression. I believe that the overall 3D
structure of the fused protein Destabilization Domain-
TagRFP-ZBTB16-V5 (Figure 1) may have masked the
destabilization domain and render it unreachable to the
proteasomal degradation signals.
ACHN cells that were used as a cell model in this study
were first transfected by the pCMV-3G plasmid to express
the 3G trans-activator that is required to bind to the tet
promoter. The selection of the best clone was based on a
luciferase assay to detect the sensitivity of each clone to Dox
induction (Figure 5). The luciferase protein was under
control of the same tetracycline responsive elements that
are part of the pTRE plasmid, the same plasmid into which
ZBTB16 was cloned. Based on responsiveness to Dox and
morphological characteristics, clone #5 was chosen for the
second round of transfection. Subsequently, this clone was
transfected with the ZBTB16 expression plasmid pTRE-
Cycle3-TagRFP-ZBTB16-V5 and selection was based on
the ability to respond to Dox treatment by expressing the
ZBTB16 fused protein. Based on protein expression, as
demonstrated by western blot, and on fluorescence intensity,
as demonstrated by fluorescence microscopy, clone #5-7 was
chosen as the cell model for this study and was designated
ACHN:ZBTB16.
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Shield1 system, the ZBTB16 expression plasmid was trans-
fected into ACHN cells that passed a double selection pro-
cess and was able to regulate the expression of ZBTB16
protein remarkably.
Conclusion
The Tet-On 3G system that was used in this study was
essential in controlling the basal expression of ZBTB16 to
prevent transcription leakage and to provide a tightly regu-
lated method for expressing the ZBTB16 protein in a fashion
resembling physiological conditions. The addition of doxy-
cycline enabled us to carefully control ZBTB16 expression in
a dose- and time-dependent manner. Shield1 was not able to
produce its desired effect of giving a second line of post-
transcriptional control; nevertheless, the Tet-On 3G system
alone was sufficient to block ZBTB16 transcriptional in the
absence of Dox. This inducible expression system of ZBTB16
in the ACHN renal adenocarcinoma cell line will be a very
valuable tool to investigate the role of ZBTB16 in effecting
the carcinogenic behaviour of these cells and possibly other
cancer cell lines.
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